JAN 23 2001 W

PTO/SB/21 (09-06)
Approved for use through 03/31/2007, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Linder the Paner	work Reduction Act of 1995	no persons				Office; U.S. DEPARTMENT OF COMMERCE pless it displays a valid OMB control number.	
Onder the Paper	WORK REGULATION ACT OF 1993	. No persons	Application Number	10/519		Iless II displays a valid OMB control Indiriper.	
TRANSMITTAL			Filing Date	July 2, 2003			
FORM			First Named Inventor	Etcheberrigaray			
			Art Unit	1614			
(to be used for all correspondence after initial filing)		Examiner Name	Not Yet Assigned				
Total Number of Pages in This Submission			Attorney Docket Number	17357.01001US			
Contraction of Eggs in this South Contraction							
ENCLOSURES (Check all that apply)							
Fee Transm	ittal Form		Drawing(s)		∐ ′	After Allowance Communication to TC	
Fee	Attached		icensing-related Papers			Appeal Communication to Board of Appeals and Interferences	
Amandmant/Bank:			Petition			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
P P			Petition to Convert to a				
After	r Final		Provisional Application Power of Attorney, Revocation	n		Proprietary Information	
		Change of Correspondence Address			Status Letter Other Enclosure(s) (please Identify		
Extension of Time Request		Ferminal Disclaimer			below):		
Express Abandonment Request		Request for Refund			•		
Information Disclosure Statement		CD, Number of CD(s)					
		Г	Landscape Table on CE)			
Certified Copy of Priority Remar		ks		<u> </u>			
		1. Re	equest for Corrected Filing Receipt				
Reply to Missing Parts/ Incomplete Application 2. C		2. Co	opy of Corrected Filing Receipt with corrections				
Reply to Missing Parts under 37 CFR 1.52 or 1.53							
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
Firm Name				RIVET, C	/ AGE	IV I	
Milbank, Tweed, Hadley & McCloy LLP							
Signature		1					
Printed name James R. Hughes							
Date January 23 , 2007			F	Reg. No.	45,65	7	
	С	ERTIFIC	ATE OF TRANSMISS	ION/MAI	LING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:							
Signature							
Typed or printed name						Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

// PATENT Attorney Docket No. 17357.01001US

OTE E SYAM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Rene Etcheberrigaray et al.) Group Art Unit: 1614
Patent Application No. 10/519,110) Examiner: Not Yet Assigned
Filed: July 2, 2003)
For: PKC Activation As A Means For Enchancing sAPPa Secretion and Improving Cognition Using Bryostatin Type Compounds))))

Commissioner of Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

SECOND REQUEST FOR CORRECTED FILING RECEIPT

Sir:

Applicants respectfully request correction of the Corrected Filing Receipt (Confirmation No.

9509) issued on January 18, 2007. Specifically, please change the following:

Title of Invention:

from Pkc activation as a means for enhancing sappa secretion and improving cognition using byrostatin type compounds" to "PKC activation as a means for enhancing sAPP alpha secretion and improving cognition using bryostatin type compounds".

Respectfully submitted,

MILBANK, TWEED, HADLEY & MCCLOY LLP

Dated: January <u>23</u>, 2007

James R. Hughes

Reg. No. 48,657

Customer No. 000038647 Milbank, Tweed, Hadley & McCloy LLP International Square Building 1825 Eye Street, N.W., Suite 1100 Washington, D.C. 20006

Telephone: (202) 835-7500 Facsimile: (202) 835-7586



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandra, Virginia 22313-1450
www.uspto.gov

FILING OR 371 APPL NO ART UNIT FIL FEE REC'D ATTY.DOCKET NO DRAWINGS **TOT CLMS** (c) DATE IND CLMS 10/519,110 02/03/2006 1614 1290 17357.01001US 16 49 3

CONFIRMATION NO. 9509

CORRECTED FILING RECEIPT

OC000000022053143

38647 MILBANK, TWEED, HADLEY & MCCLOY LLP INTERNATIONAL SQUARE BUILDING 1850 K STRET, N.W., SUITE 1100 WASHINGTON, DC 20006

Date Mailed: 01/18/2007

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Rene Etcheberrigaray, Bethesda, MD; Daniel L. Alkon, Bethesda, MD;

Assignment For Published Patent Application

Blanchette Rockefeller Neurosciences Institute, Bethesda Maryland, MD

Power of Attorney: The patent practitioners associated with Customer Number 38647.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US03/20820 07/02/2003 which claims benefit of 60/392,951 07/02/2002

Foreign Applications

If Required, Foreign Filing License Granted: 11/07/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10/519,110

Projected Publication Date: 02/15/2007

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

PKC

sAPP alpha

Pke activation as a means for enhancing sappalpha secretion and improving cognition using bryostatin type compounds

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier

license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).